Proteasome inhibition enhances antitumour effects of gemcitabine in experimental pancreatic cancer

HPB

Volumn 11, Issue 7, 2009, Pages 600-605

  Awasthi, Niranjan ^a   Schwarz, Margaret A ^a   Schwarz, Roderich E ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Bortezomib combination therapy; Experimental therapy; Pancreatic cancer; Proteasome inhibition

Indexed keywords

BORTEZOMIB; GEMCITABINE; PROTEASOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 73349129983     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2009.00109.x     Document Type: Article

References (21)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. (2007) Cancer statistics. CA Cancer J Clin 57:43-66..
2. Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C et al. (2005) Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 6:369-376.
3. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd. (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20:3270-3275.
4. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T et al. (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509-3516.
5. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. (2002) A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161-167.
6. Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK et al. (2008) A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs 26:463-471.
7. Matthews W, Driscoll J, Tanaka K, Ichihara A, Goldberg AL. (1989) Involvement of the proteasome in various degradative processes in mammalian cells. Proc Natl Acad Sci U S A 86:2597-2601.
8. Adams J. (2004) The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5:417-421.
9. Cusack JC. (2003) Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 29 (Suppl. 1):21-31.
10. Tang ZY, Wu YL, Gao SL, Shen HW. (2008) Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells. J Surg Res 145:111-123.
11. Nawrocki ST, Bruns CJ, Harbison MT, Bold RJ, Gotsch BS, Abbruzzese JL et al. (2002) Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 1:1243-1253.
12. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Dunner K Jr, Huang P et al. (2005) Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 65:11658-11666.
13. Fahy BN, Schlieman MG, Virudachalam S, Bold RJ. (2003) Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer. J Surg Res 113:88-95.
14. Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ et al. (2001) 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 82:110-122.
15. Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ. (2004) The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 3:59-70.
16. Alberts SR, Foster NR, Morton RF, Kugler J, Schaefer P, Wiesenfeld M et al. (2005) PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study. Ann Oncol 16:1654-1661.
17. Awasthi N, Schwarz MA, Verma V, Cappiello C, Schwarz RE. (2009) Endothelial monocyte activating polypeptide II interferes with VEGFinduced proangiogenic signaling. Lab Invest 89:38-46.
18. Schwarz RE, McCarty TM, Peralta EA, Diamond DJ, Ellenhorn JD. (1999) An orthotopic in vivo model of human pancreatic cancer. Surgery 126:562-567.
19. Bold RJ, Virudachalam S, McConkey DJ. (2001) Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 100:11-17.
20. Akada M, Crnogorac-Jurcevic T, Lattimore S, Mahon P, Lopes R, Sunamura M et al. (2005) Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clin Cancer Res 11:3094-3101.
21. Marten A, Zeiss N, Serba S, Mehrle S, von Lilienfeld-Toal M, Schmidt J. (2008) Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma. Mol Cancer Ther 7:3624-3631.